Genomic Consideration in Chemotherapy-Induced Ovarian Damage and Fertility Preservation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seongmin | - |
dc.contributor.author | Lee, Sanghoon | - |
dc.contributor.author | Park, Hyun-Tae | - |
dc.contributor.author | Song, Jae-Yun | - |
dc.contributor.author | Kim, Tak | - |
dc.date.accessioned | 2022-02-18T16:41:15Z | - |
dc.date.available | 2022-02-18T16:41:15Z | - |
dc.date.created | 2022-02-08 | - |
dc.date.issued | 2021-10 | - |
dc.identifier.issn | 2073-4425 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/136244 | - |
dc.description.abstract | Chemotherapy-induced ovarian damage and fertility preservation in young patients with cancer are emerging disciplines. The mechanism of treatment-related gonadal damage provides important information for targeting prevention methods. The genomic aspects of ovarian damage after chemotherapy are not fully understood. Several studies have demonstrated that gene alterations related to follicular apoptosis or accelerated follicle activation are related to ovarian insufficiency and susceptibility to ovarian damage following chemotherapy. This may accelerate follicular apoptosis and follicle reservoir utilization and damage the ovarian stroma via multiple molecular reactions after chemotherapy. This review highlights the importance of genomic considerations in chemotherapy-induced ovarian damage and multidisciplinary oncofertility strategies for providing high-quality care to young female cancer patients. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.subject | BRCA MUTATION CARRIERS | - |
dc.subject | PRIMORDIAL GERM-CELLS | - |
dc.subject | HEAT-SHOCK FACTOR-1 | - |
dc.subject | YOUNG-WOMEN | - |
dc.subject | STEM-CELLS | - |
dc.subject | OOCYTE CRYOPRESERVATION | - |
dc.subject | EMBRYO CRYOPRESERVATION | - |
dc.subject | TARGETED DISRUPTION | - |
dc.subject | CHROMOSOME SYNAPSIS | - |
dc.subject | CANCER STATISTICS | - |
dc.title | Genomic Consideration in Chemotherapy-Induced Ovarian Damage and Fertility Preservation | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Sanghoon | - |
dc.contributor.affiliatedAuthor | Kim, Tak | - |
dc.identifier.doi | 10.3390/genes12101525 | - |
dc.identifier.scopusid | 2-s2.0-85116112507 | - |
dc.identifier.wosid | 000711398400001 | - |
dc.identifier.bibliographicCitation | GENES, v.12, no.10 | - |
dc.relation.isPartOf | GENES | - |
dc.citation.title | GENES | - |
dc.citation.volume | 12 | - |
dc.citation.number | 10 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Genetics & Heredity | - |
dc.relation.journalWebOfScienceCategory | Genetics & Heredity | - |
dc.subject.keywordPlus | BRCA MUTATION CARRIERS | - |
dc.subject.keywordPlus | CANCER STATISTICS | - |
dc.subject.keywordPlus | CHROMOSOME SYNAPSIS | - |
dc.subject.keywordPlus | EMBRYO CRYOPRESERVATION | - |
dc.subject.keywordPlus | HEAT-SHOCK FACTOR-1 | - |
dc.subject.keywordPlus | OOCYTE CRYOPRESERVATION | - |
dc.subject.keywordPlus | PRIMORDIAL GERM-CELLS | - |
dc.subject.keywordPlus | STEM-CELLS | - |
dc.subject.keywordPlus | TARGETED DISRUPTION | - |
dc.subject.keywordPlus | YOUNG-WOMEN | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.subject.keywordAuthor | cryopreservation | - |
dc.subject.keywordAuthor | fertility preservation | - |
dc.subject.keywordAuthor | gene | - |
dc.subject.keywordAuthor | gonadotoxicity | - |
dc.subject.keywordAuthor | mutation | - |
dc.subject.keywordAuthor | oncofertility | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.